Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19178522 | BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS | April 2025 | November 2025 | Allow | 7 | 1 | 0 | No | No |
| 18332612 | Cells selected for high mitochondria and/or reactive oxygen species for use as packaging cells for gene theraphy vectors and viral vaccines | June 2023 | January 2026 | Abandon | 31 | 4 | 2 | Yes | No |
| 18324475 | METHODS AND SYSTEMS FOR PROCESSING A NUCLEIC ACID SAMPLE | May 2023 | December 2025 | Abandon | 30 | 5 | 0 | Yes | No |
| 18298529 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | April 2023 | November 2025 | Allow | 31 | 0 | 0 | No | No |
| 17980200 | NASAL-SPRAY SAMPLING | November 2022 | March 2026 | Abandon | 40 | 1 | 1 | Yes | No |
| 17888131 | VACCINES AND USES THEREOF TO INDUCE AN IMMUNE RESPONSE TO SARS-COV2 | August 2022 | August 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17760227 | VIRUS-FREE CELL CULTURES | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17783120 | METHODS FOR TREATING BACTERIAL INFECTIONS | June 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17770641 | CHIMERIC POLYPEPTIDES AND USES THEREOF | April 2022 | February 2026 | Allow | 46 | 2 | 0 | No | No |
| 17762472 | COMPOSITION AND METHOD FOR IMPROVING DETECTION OF BIOMOLECULES IN BIOFLUID SAMPLES | March 2022 | February 2026 | Allow | 47 | 1 | 1 | No | No |
| 17638630 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION | February 2022 | March 2026 | Allow | 48 | 1 | 0 | No | No |
| 17637829 | ANTIBODIES AND THE USES THEREOF | February 2022 | November 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17629592 | SINGLE PLASMID VECTOR SYSTEM FOR PACKAGING RECOMBINANT HUMAN ADENOVIRUS TYPE 4 AND APPLICATION THEREOF | January 2022 | September 2025 | Allow | 44 | 1 | 0 | No | No |
| 17596401 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | December 2021 | November 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17611564 | PEPTIDE VACCINE BASED ON A NEW UNIVERSAL INFLUENZA A HEMAGGLUTININ HEAD DOMAIN EPITOPE AND HUMAN MONOCLONAL ANTIBODIES BINDING THERETO | November 2021 | August 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17594113 | MULTIPLEX COMPETITION ASSAY FOR PROFILING BINDING EPITOPES OF AFFINITY AGENTS FOR CLINICAL DIAGNOSTICS USE | October 2021 | November 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17472268 | Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus Vaccine | September 2021 | January 2026 | Abandon | 52 | 5 | 1 | Yes | No |
| 17314983 | METHOD OF DETECTING PATHOGENS AND/OR ANTIGENS IN SAMPLES | May 2021 | November 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17291906 | COMPOSITIONS AND METHODS OF INDUCING DIFFERENTIATION OF A HAIR CELL | May 2021 | February 2026 | Abandon | 57 | 4 | 0 | No | No |
| 17236213 | HUMAN MEDICAL PROPHYLAXIS OF CORONAVIRIDAE PATHOGENIC INFECTION BY TOPICAL APPLICATION OF IMMUNE CORONAVIRIDAE IMMUNOGLOBULIN A | April 2021 | November 2025 | Abandon | 55 | 4 | 1 | Yes | No |
| 17275310 | Anti-HIV Antibody 10-1074 Variants | March 2021 | May 2025 | Allow | 50 | 2 | 2 | Yes | No |
| 16942156 | ADENOVIRUS-ASSOCIATED VIRUSES SEPARATION METHOD | July 2020 | October 2025 | Abandon | 60 | 2 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WANG, RUIXUE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WANG, RUIXUE works in Art Unit 1672 and has examined 9 patent applications in our dataset. With an allowance rate of 33.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 52 months.
Examiner WANG, RUIXUE's allowance rate of 33.3% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WANG, RUIXUE receive 2.44 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WANG, RUIXUE is 52 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +60.0% benefit to allowance rate for applications examined by WANG, RUIXUE. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.5% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.